Oxford Capital Partners

Oxford Capital Partners is a UK-based investment firm with a visible website, LinkedIn and Crunchbase presence and a long history of investing across UK growth companies, with historical exposure spanning early venture, growth and infrastructure-style mandates. The source data carries no disclosed healthcare thesis or AI focus, but the firm’s broader positioning suggests selective UK and European participation in growth-stage opportunities, frequently leveraging tax-advantaged investment structures such as EIS for UK private clients. For healthcare founders, Oxford Capital is most relevant if you are a UK-incorporated company eligible for EIS or similar wrappers, with traction sufficient to fit a growth-style mandate, or if you are raising a UK-led Series A or B with a clear path to exit. Check sizes can vary widely depending on which strategy is deploying, plausibly GBP 500K to several million at venture, more at growth-stage. The firm is a poor fit for US-based founders, pre-revenue therapeutics, capital-intensive devices and any company without UK incorporation or operations. Founders should expect financial-led diligence with strong emphasis on commercial proof, governance and exit pathway. Entry is best via UK-based corporate finance advisors, lawyers familiar with EIS deal flow, or portfolio founder introductions; LinkedIn outreach to investment principals is workable. Founders should explicitly clarify which fund or strategy the prospective investment would come from, EIS implications if any, lead-versus-participant posture, and current healthcare exposure in the relevant strategy before investing meaningful diligence cycles.